RT Journal Article
T1 Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
A1 Martin, Miguel
A1 Brase, Jan C
A1 Ruiz, Amparo
A1 Prat, Aleix
A1 Kronenwett, Ralf
A1 Calvo, Lourdes
A1 Petry, Christoph
A1 Bernard, Philip S
A1 Ruiz-Borrego, Manuel
A1 Weber, Karsten E
A1 Rodriguez, César A
A1 Alvarez, Isabel M
A1 Segui, Miguel A
A1 Perou, Charles M
A1 Casas, Maribel
A1 Carrasco, Eva
A1 Caballero, Rosalía
A1 Rodriguez-Lescure, Alvaro
K1 Breast cancer
K1 Chemotherapy
K1 EndoPredict
K1 PAM50
K1 Prognosis
AB There are several prognostic multigene-based tests for managing breast cancer (BC), but limited data comparing them in the same cohort. We compared the prognostic performance of the EndoPredict (EP) test (standardized for pathology laboratory) with the research-based PAM50 non-standardized qRT-PCR assay in node-positive estrogen receptor-positive (ER+) and HER2-negative (HER2-) BC patients receiving adjuvant chemotherapy followed by endocrine therapy (ET) in the GEICAM/9906 trial. EP and PAM50 risk of recurrence (ROR) scores [based on subtype (ROR-S) and on subtype and proliferation (ROR-P)] were compared in 536 ER+/HER2- patients. Scores combined with clinical information were evaluated: ROR-T (ROR-S, tumor size), ROR-PT (ROR-P, tumor size), and EPclin (EP, tumor size, nodal status). Patients were assigned to risk-categories according to prespecified cutoffs. Distant metastasis-free survival (MFS) was analyzed by Kaplan-Meier. ROR-S, ROR-P, and EP scores identified a low-risk group with a relative better outcome (10-year MFS: ROR-S 87 %; ROR-P 89 %; EP 93 %). There was no significant difference between tests. Predictors including clinical information showed superior prognostic performance compared to molecular scores alone (10-year MFS, low-risk group: ROR-T 88 %; ROR-PT 92 %; EPclin 100 %). The EPclin-based risk stratification achieved a significantly improved prediction of MFS compared to ROR-T, but not ROR-PT. All signatures added prognostic information to common clinical parameters. EPclin provided independent prognostic information beyond ROR-T and ROR-PT. ROR and EP can reliably predict risk of distant metastasis in node-positive ER+/HER2- BC patients treated with chemotherapy and ET. Addition of clinical parameters into risk scores improves their prognostic ability.
YR 2016
FD 2016-02-24
LK http://hdl.handle.net/10668/9862
UL http://hdl.handle.net/10668/9862
LA en
DS RISalud
RD Apr 14, 2025